We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Calcium channel blockers, angiotensin II receptor blockers (ARBs) and compound preparations accounted for more than half of the market shares among the antihypertensive drugs in China in 2015, separately accounting for 35%, 26% and 16%.